You are on page 1of 8

Acute Care1111Page

Floor Nurses
Guide:
1 of 8
Intravenous Push (IVP) Drug List Approved for RN Administration
University of Kentucky Chandler Medical Center

4/10/07

If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual situation must be
obtained through collaboration with pharmacy and the patient care manager
GENERIC NAME
(BRAND NAME(S))

RESTRICTED
AREA

THERAPEUTIC
CATEGORY

TYPICAL
ADULT
DOSE

MAXIMUM
ADULT
DOSE

MAXIMUM
CONCENTRA
TION*

MAXIMUM RATE
OF
ADMINISTRATION
**

ADMINISTRATION
CONSIDERATIONS

ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS

Bumetanide
(Bumex)

Diuretic/Acute
Pulmonary Edema,
CHF, and Renal
disease

0.5-2 mg
over 1-2
minutes

10 mg/day

0.25 mg/ml

2 mg over 2
minutes

Pain at injection
Site

Monitor labs; Multiple drug


interactions; dizziness; N&V,
hypotension, and decrease
calcium and K+

Chlorothiazide Sodium
(Diuril)

Diuretic/Antihypertensive agent

0.5 1 g

2 g/day

28 mg/ml

Slow IVP

Extravasation
MUST be
avoided. Do
NOT give SC or
IM

Monitor electrolytes, rash,


hypotension

Cosyntropin (Cortrosyn) -

Diagnostic Agent

1 mcg or
250 mcg

250 750
mcg

Over 2 minutes

Blood draws
must be at
specific times
indicated by MD
order. No
steroids or
spironolactone
day before or
day of test.

Hypertension, flushing.
Peak cortisol concentration
occurs 45-60 min after
administration

Dexamethasone Sodium Phosphate


(Decadron)

Antiemetic; Antiinflammatory

4 mg

10 mg

4 mg/ml

Maximum rate:
Over 1 minute
Slower if itching
Over 3-5 minutes

Insomnia, nervousness,
increased appetite, fluid
retention

Dextrose 50%

Carbohydrate/
Symptomatic
hyperglycemia

25 gm

25 gm/50ml

10 ml/min

Phlebitis risk,
pain at injection
site; Large bore
IV access

Hyperglycemia, confusion

Page 1 of 8

Acute Care2222Page
Floor Nurses
Guide:
2 of 8
Intravenous Push (IVP) Drug List Approved for RN Administration
University of Kentucky Chandler Medical Center

4/10/07

If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual situation must be
obtained through collaboration with pharmacy and the patient care manager
GENERIC NAME
(BRAND NAME(S))

RESTRICTED
AREA

THERAPEUTIC
CATEGORY

TYPICAL
ADULT
DOSE

MAXIMUM
ADULT
DOSE

MAXIMUM
CONCENTRA
TION*

MAXIMUM RATE
OF
ADMINISTRATION
**

ADMINISTRATION
CONSIDERATIONS

ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS

Diazepam
(Valium)

Benzodiazepine;
Anti-anxiety,
Anticonvulsant,

2-10mg/
dose

30 mg/8hrs

5 mg/ml

5 mg/minute

Phlebitis risk,
pain at injection
site
0.22 micron
filter required for
IVPB admin

Bradycardia; tachycardia,
drowsiness, hypotension,
hypoventilation

Dihydroergotamine
(D.H.E 45)

Antimigraine Agent

0.31mg/dose

6 mg/week

1mg/ml

Over 2-3minutes

HTN, Headache, dizziness, N/V

Diphenhydramine HCL (Benadryl)

Antihistamine;
Histamine 1
Antagonist

12.5-50 mg
q 2-4H

50 mg/dose
400 mg/day

50 mg/ml

25 mg/minute

Dilute to 25 mg/
ml in D5W or
NS

Hypotension, tachycardia,
sedation, dizziness, insomnia

Dolasetron Mesylate
(Anzemet)

Antiemetic

12.5 mg
over 30
seconds

25 mg

12.5 mg/
0.625 ml

25 mg over 30
seconds

Caution in
patients at risk
for prolonged
QT interval

HTN, headache, urinary


retention, tachycardia

Epinephrine
(Adrenaline Chloride)

Anaphylaxis/
Sympathomimetic

0.3-0.5 mg
IM/SQ
every 1520 minutes
as needed

1mg/ml

1mg/min

Watch for
injection site
blanching/
Extravasation
Use 1:1000 in
anaphylaxis

Tachycardia, hypertension,
nervousness, restlessness,
headache, dizziness
HR, BP

Gastrointestinal;
Histamine 2
Antagonist

20 mg q
12H

40 mg

20 mg/5ml

20 mg over 2
minutes

Headaches, dizziness, confusion,


mental status changes

Anaphylaxis Only

Famotidine
(Pepcid)

Page 2 of 8

Acute Care3333Page
Floor Nurses
Guide:
3 of 8
Intravenous Push (IVP) Drug List Approved for RN Administration
University of Kentucky Chandler Medical Center

4/10/07

If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual situation must be
obtained through collaboration with pharmacy and the patient care manager
GENERIC NAME
(BRAND NAME(S))

RESTRICTED
AREA

THERAPEUTIC
CATEGORY

TYPICAL
ADULT
DOSE

MAXIMUM
ADULT
DOSE

MAXIMUM
CONCENTRA
TION*

MAXIMUM RATE
OF
ADMINISTRATION
**

ADMINISTRATION
CONSIDERATIONS

ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS

Flumazenil
(Rumazicon)

Benzodiazepine
Antagonist

0.2 mg
over 30
seconds
initial, can
repeat with
0.3mg

Give no
more than
1 mg per
dose or
3mg/hour

0.1mg/ml

0.2 mg over
15-30 seconds

Use large vein


and free flowing
IV to minimize
pain

Pt. may need additional doses in


case of re-sedation. Caution with
seizure patient.

Furosemide
(Lasix)

Loop Diuretic/
Volume overload

20 - 40 mg

80 mg but
can vary
widely

10 mg/ml

1-2 minutes
(Consider IVPB
over 5-10
minutes)

Hypotension, headache, and


dizziness

Glucagon

Emergency treatment
of symptomatic
hypoglycemia

0.5-1 mg/
min
(May be
repeated 12 times)

1 mg/ml

1 mg/min

May precipitate
with NS, K+
and Calcium;
Compatible
with D5W

Unstable hypoglycemic diabetic


may not respond & will need IV
Dextrose instead;
N/V, hypokalemia in overdose,
urticaria, respiratory distress and
hypotension

5HT3 Blocker
Prevention of N/V
secondary to
chemotherapy

10 mcg/kg
given 30
minutes
prior to
chemo

Antipsychotic/
Agitation

2-5 mg

Granisetron HCL
(Kytril)

Haloperidol Lactate
(Haldol)

Undiluted over
30 seconds

Varies with
patient

5 mg/ml

5 mg/min

Headache, diarrhea,
constipation, hypertension, fever

Start with lower


doses in geriatric
patients

Drowsiness, hypotension,
Extrapyramidal effects,
bradycardia, tachycardia

Page 3 of 8

Acute Care4444Page
Floor Nurses
Guide:
4 of 8
Intravenous Push (IVP) Drug List Approved for RN Administration
University of Kentucky Chandler Medical Center

4/10/07

If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual situation must be
obtained through collaboration with pharmacy and the patient care manager
GENERIC NAME
(BRAND NAME(S))

RESTRICTED
AREA

THERAPEUTIC
CATEGORY

TYPICAL
ADULT
DOSE

MAXIMUM
ADULT
DOSE

MAXIMUM
CONCENTRA
TION*

MAXIMUM RATE
OF
ADMINISTRATION
**

ADMINISTRATION
CONSIDERATIONS

ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS

Heparin Bolus
(Heparin Drip
Protocol)

Anti-coagulant

Varies3,000-8,000
units

8,000 units

Usual:
10,000
units/mL

Over 1 minute

Antagonist is
Protamine

Bleeding, APTT, HCT, Hgb


Thrombocytopenia (HITHeparin induced)

Heparin
(for flush of Central
line catheter)

Anti-coagulant

100 units/ml

Antagonist is
Protamine

Bleeding, APTT, HCT, Hgb


Thrombocytopenia (HITHeparin induced)

Hydrocortisone
Sodium Phosphate
(Hydrocortone
Phosphate)

Anti-inflammatory
agent Corticosteroid

300 units
instilled
into Central
Catheter
15-240 mg

50 mg/ml

Over 3-5 minutes

Insomnia, nervousness
BP

Hydrocortisone
Succinate (SoluCortef)

Anti-inflammatory
(IV given usually in
emergency)

15-240 mg

1 gm/24
hour

Over 1 minute

Caution in
elderly
May need to
taper therapy

Monitor electrolytes; May mask


signs of infection

Hydromorphone
(Dilaudid)

Narcotic Analgesic

1-4 mg

4 mg/ml

Each 1 mg over
2-3 minutes

Reversal agent
Naloxone
(Narcan)

Palpitations, hypotension,
dizziness, drowsiness, BP, RR

Insulin (Regular only)

Pancreatic Hormone/
Hyperglycemia

5-10 units
over 10
seconds

10 units

10 seconds

Push for
hyperkalemia
only; Only
Regular Insulin
can be given IV

Monitor Finger Stick Blood


Sugars

Push for
hyperKalemia only

Page 4 of 8

Acute Care5555Page
Floor Nurses
Guide:
5 of 8
Intravenous Push (IVP) Drug List Approved for RN Administration
University of Kentucky Chandler Medical Center

4/10/07

If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual situation must be
obtained through collaboration with pharmacy and the patient care manager
GENERIC NAME
(BRAND NAME(S))

RESTRICTED
AREA

THERAPEUTIC
CATEGORY

TYPICAL
ADULT
DOSE

MAXIMUM
ADULT
DOSE

MAXIMUM
CONCENTRA
TION*

MAXIMUM RATE
OF
ADMINISTRATION
**

ADMINISTRATION
CONSIDERATIONS

ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS

Ketorolac
(Toradol)

NSAID/Short-term
management of modsevere pain

15- 30 mg
IV q 6
hours

120 mg/day
Max. 5
days

30 mg/ml

Over > 15
seconds

Requires renal
dose adjustment

Edema, drowsiness, headache


Avoid in patients with active or
recent bleeds

Levothyroxine
(Synthroid)

Thyroid hormone

50-100mcg

100 mcg/ml

100mcg/min

-Prepare
immediately
before
administration,
with 5ml Normal
saline.
-Do not mix with
any other IVF
-Do not further
dilute drug

Symptoms of hyperthyroidism
nervousness, tremor, headache,
tachycardia, heat intolerance,
etc.

( of oral
dose)

Lorazepam
(Ativan)

Benzodiazapine

2-4 mg
diluted
with equal
volume of
IVF

8 mg/12hrs

2 mg/ml

2 mg/minute

Can easily cause


infiltration with
IVP,
Consider IVPB
over 5-10 min;
Reversal agentFlumazenil

Sedation, hypotension, dizziness,


headache, HR, BP, RR

Meperidine
(Demerol)

Narcotic Analgesic

25-100 mg
q 2-4 hours

100 mg/ml

Over 5 minutes

Dilute to 10 mg/
ml with NS
Reversal agentNaloxone
(Narcan)

Sedation, hypotension, dizziness,


BR, RR

Page 5 of 8

Acute Care6666Page
Floor Nurses
Guide:
6 of 8
Intravenous Push (IVP) Drug List Approved for RN Administration
University of Kentucky Chandler Medical Center

4/10/07

If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual situation must be
obtained through collaboration with pharmacy and the patient care manager
GENERIC NAME
(BRAND NAME(S))

RESTRICTED
AREA

THERAPEUTIC
CATEGORY

TYPICAL
ADULT
DOSE

MAXIMUM
ADULT
DOSE

MAXIMUM
CONCENTRA
TION*

MAXIMUM RATE
OF
ADMINISTRATION
**

ADMINISTRATION
CONSIDERATIONS

ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS

Methylprednisolone
Sodium Succinate
(Solu-Medrol)

Anti-inflammatory
agent/ Adrenal
Corticosteroid

40-250 mg

62.5 mg/ml

125 mg over 3-5


minutes
Higher doses
give IVPB

Only the
succinate form
can be given IV;
Rapid admin. Of
high doses can
cause circulatory
collapse

Insomnia, nervousness
BP, Monitor Na+ and K+, FSBS

Metoclopramide
(Reglan)

Cholinergic/ GI
stimulant
Antiemetic

5-10 mg

10 mg

5 mg/ml

10mg or fraction
thereof over 2
minutes
>10 mg IVPB
over 15 minutes

Too rapid rate


may cause
intense anxiety
& restlessness

Hypotension, SVT, sedation,


dizziness, rash, extrapyramidal
effects treat with Benadryl:
Caution with hypertension

Morphine

Narcotic Analgesic

1-4 mg

8 mg

10 mg/ml

1 mg/min

Reversal agent
Naloxone
(Narcan)

Sedation, dizziness, heart


palpitation, hypotension,
bradycardia, and respiratory
depression
BP, RR, Oxygen saturation

Muromonab-CD3
(Orthoclone, OKT3)

8E

Immunosuppressive
Agent/ Rejection

5 mg

5 mg

1 mg/ml

<1-2 minute

Filter each dose


through a low
protein binding
0.22 micron
filter

Fever, chilling, dyspnea,


wheezing, chest pain,
tachycardia, dizziness, shortness
of breath,
HR, BP, RR, Temperature

Page 6 of 8

Acute Care7777Page
Floor Nurses
Guide:
7 of 8
Intravenous Push (IVP) Drug List Approved for RN Administration
University of Kentucky Chandler Medical Center

4/10/07

If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual situation must be
obtained through collaboration with pharmacy and the patient care manager
GENERIC NAME
(BRAND NAME(S))

RESTRICTED
AREA

THERAPEUTIC
CATEGORY

TYPICAL
ADULT
DOSE

MAXIMUM
ADULT
DOSE

MAXIMUM
CONCENTRA
TION*

MAXIMUM RATE
OF
ADMINISTRATION
**

ADMINISTRATION
CONSIDERATIONS

ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS

Naloxone
(Narcan)

Pure Opioid
Antagonist

0.1-0.8 mg

24 mg

1 mg/ml

Administer a
dilute solution of
naloxone (0.4mg
in 10 ml of saline)
IV, very slowly
(0.5ml over 2
minutes) while
you watch for the
desired effect
(titrate to effect).
The patient should
open his eyes
within one to two
minutes. If not,
continue giving
naloxone at the
same rate up to 0.8
mg or 20 mls of
dilute solution.

If patient does
not arouse after
the initial
administration
of Naloxone
(total dose of
0.8mg) begin
looking for
other causes of
sedation and
respiratory
depression.

Tachycardia, narcotic withdraw,


hypertension, hypotension,
anxiety, restlessness, Pulmonary
Edema, HR, BP, RR

Ondansetron (Zofran)

Antiemetic

1-4 mg

4 mg

1-4 mg over 2-5


minutes

Incompatible
with numerous
drugs

Observe closely for respiratory


distress; Ambulate Slowly

Reconstitute
with 10ml, 0.9%
Normal Saline

Injection site reactions,


headache, dyspepsia, and nausea

Pantoprazole
(Protonix)

Gastrointestinal;
Proton pump
inhibitor

40 mg

80 mg

4 mg/ml

4 mg
consider
IVPB
over 15
minutes

40 mg over 2
minutes

Page 7 of 8

Acute Care8888Page
Floor Nurses
Guide:
8 of 8
Intravenous Push (IVP) Drug List Approved for RN Administration
University of Kentucky Chandler Medical Center

4/10/07

If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual situation must be
obtained through collaboration with pharmacy and the patient care manager
GENERIC NAME
(BRAND NAME(S))

RESTRICTED
AREA

THERAPEUTIC
CATEGORY

Promethazine
Antiemetic/
(Phenegran) IVP only
Antihistamine
with Central or
PICC Line or IVPB
over 20 mins
* Alter volume based upon dosage to be administered

TYPICAL
ADULT
DOSE

12.5-25 mg

MAXIMUM
ADULT
DOSE

50 mg

MAXIMUM
CONCENTRA
TION*

MAXIMUM RATE
OF
ADMINISTRATION
**

ADMINISTRATION
CONSIDERATIONS

50 mg/ml

IVP: 25 mg/min

Monitor for
infiltration

ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS

Hypotension, tachycardia,
dizziness, and drowsiness

IVPB: 20
minutes
** Alter duration based upon dose to be administered.

If the medication is not approved for IV push administration and alternative routes of administration are not available, approval for this
individual situation must be obtained through collaboration with pharmacy and the patient care manager

Updated: 04/10/07
Revised by: Christy Taylor, PharmD and Lori Proeschel, PharmD
Contact person for revisions: Kimberley Hite (khite2@uky.edu)

Page 8 of 8

You might also like